MedTrace Logo

Respiratory Virus Hospitalization Study (FLU 003 Plus)

NCT01056185 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-10-21

No results posted yet for this study

Summary

Following the sudden and unexpected emergence of influenza A(H1N1)pdm09 (2009 H1N1) virus, this observational study was initiated to estimate rates of morbidity and mortality and to examine predictors of severity among participants with 2009 H1N1 infection. In 2011, as surveillance indicated that 2009 H1N1 virus was co-circulating with other seasonal influenza A and B viruses worldwide, the protocol was expanded to include other influenza A subtypes and influenza B viruses. The current version of the protocol (released in August 2013) further broadens the scope of this observational study. With the recognition that novel respiratory viruses other than novel influenza A viruses, e.g., Middle East Respiratory Syndrome Coronavirus (MERS-CoV), could become prevalent and of major public health importance, the objectives of this protocol have been expanded.

Conditions

  • Influenza
  • Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV)
  • Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • Clinical & Translational Science Institute, University of Minnesota

    collaborator UNKNOWN

  • University of Minnesota

    lead OTHER

Principal Investigators

  • Cavan Reilly, PhD · University of Minnesota - Dept Biostatistics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2024-08-30
Completion
2024-08-30

Countries

  • United States
  • Argentina
  • Australia
  • Belgium
  • Chile
  • Denmark
  • Germany
  • Greece
  • Peru
  • Spain
  • Thailand
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01056185 on ClinicalTrials.gov